Biodel, stem-cell biotechs lead drug stock south

BOSTON (MarketWatch) -- Biodel Inc. led drug stocks south early Tuesday as shares of the biotech company fell on news that the U.S. Food and Drug Administration has issued a warning letter to one of its contract product manufacturers.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.